Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)

Taiwan · Delayed Price · Currency is TWD

30.05

+0.05 (0.17%)

Nov 13, 2026, 1:30 PM CST

Market Cap	6.06B +1.9%
Revenue (ttm)	3.45B +7.1%
Net Income	351.67M +13.5%
EPS	1.74 +13.2%
Shares Out	201.61M
PE Ratio	17.31
Forward PE	n/a
Dividend	0.94 (3.14%)
Ex-Dividend Date	Jul 24, 2026

Volume	129,689
Open	30.00
Previous Close	30.00
Day's Range	30.00 - 30.25
52-Week Range	28.11 - 32.80
Beta	0.14
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 19, 2026

About Sinphar Pharmaceutical

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and oth... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1977

Country Taiwan

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 1734

Full Company Profile

Financial Performance

In 2025, Sinphar Pharmaceutical's revenue was 3.37 billion, an increase of 7.00% compared to the previous year's 3.15 billion. Earnings were 365.75 million, an increase of 20.03%.

Financial Statements